Cyclooxygenase-2: A major therapeutic advance?

American Journal of Medicine

Volumn 110, Issue 1 SUPPL. 1, 2001, Pages S42-S45

  Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; MEDICAL PRACTICE; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0035825166     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00649-5     Document Type: Review

References (38)

1. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs
2. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
3. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation
4. Cyclooxygenase in biology and disease
5. Safety and efficacy of celecoxib, a specific COX-2 inhibitor
6. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
7. COX-2 in synovial tissues
8. COX-1 and COX-2 tissue expression: Implications and predictions
9. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
10. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
11. Efficacy and safety of celecoxib, a specific cyclooxygenase-2 inhibitor, in rheumatoid arthritis
12. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
13. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
14. Efficacy and tolerability of celecoxib, a COX-2 specific inhibitor, for treating the pain and inflammation of osteoarthritis
15. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: A randomised, controlled trial
16. Efficacy and tolerability of celecoxib: A comparison of once-daily vs twice-daily dosing
17. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib
18. Celecoxib 200 mg administered once-a-day or in split doses has equal impact on health-related quality of life (HRQOL) of patients with osteoarthritis (OA)
19. Efficacy of celecoxib, a COX-2 specific inhibitor, in osteoarthritis of the hip
20. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib
21. Rofecoxib, a COX-2 specific inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of the knee and hip osteoarthritis in a 6-week controlled clinical trial
22. Rofecoxib, a specific inhibitor of cyclooxygenase-2 with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year randomised clinical trial in patients with osteoarthritis of the knee and hip
23. The structure of human cyclooxygenase-2: Conservation and flexibility of the NSAID binding site
24. 2) synthesis in healthy humans
25. Evidence that the COX-2 specific inhibitor rofecoxib at 50 mg spares gastric mucosal prostaglandin synthesis in humans
26. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
27. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastrointestinal damage than either aspirin or ibuprofen
28. Effect of the COX-2 specific inhibitor (C-2SI) rofecoxib on ulcer formation: A double-blind comparison with ibuprofen and placebo
29. Comparison of the effect of rofecoxib (a cyclooxygenase 2 specific inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis
30. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomised controlled trial
31. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
32. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OS) and rheumatoid arthritis (RA) patients as compared to NSAIDs
33. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota, 1980 through 1984
34. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
35. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
36. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
37. Cardiovascular safety profile of rofecoxib in controlled clinical trials